Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
80%(4 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
1
20%
Ph phase_3
3
60%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

NCT02597478
completedphase_1

Fentanyl Sublingual Spray in Opioid Naive Participants

NCT02641340
completedphase_3

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
completedphase_3

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

NCT00538863
completedphase_3

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

NCT00956254

Clinical Trials (5)

Showing 5 of 5 trials
NCT02597478Phase 2

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Completed
NCT02641340Phase 1

Fentanyl Sublingual Spray in Opioid Naive Participants

Completed
NCT00538850Phase 3

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Completed
NCT00538863Phase 3

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

Completed
NCT00956254Phase 3

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5